Phenotypes Associated with This Genotype

Genotype
MGI:4819951

• Allelic Composition: Tg(Camk2a-tTA)1Mmay/?; Fgf14^{Tg(tetO-MAPT*P301L)4510Kha}/?
• Genetic Background: involves: 129S6/SvEvTac * FVB/N

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

nervous system

decreased brain weight ( J:99626 )

• a significant loss in brain weight by 5.5 months

• when treated with doxycycline during 5.5 to 10 months, the loss of brain weight was significantly protected

abnormal hippocampus CA1 region morphology ( J:99626 )

• significant decrease in total numbers of CA1 hippocampal neurons

• CA1 neuron estimates were stabilized after brief (6- to 8-week) doxycycline treatment

forebrain atrophy ( J:99626 )

• gross atrophy of the forebrain was evident in a 10-month-old mouse

neurofibrillary tangles ( J:99626 )

• develop argyrophilic tangle-like inclusions in the cortex by 4 months and in the hippocampal formation by 5.5 months

• when treated with doxycycline at 2.5 month, the tau pathology ceased to progress

abnormal neuron morphology ( J:99626 )

• the neuronal inclusions composed of a mass of straight tau filaments

• when treated with doxycycline at 2.5 month, the tau pathology ceased to progress

decreased hippocampus pyramidal cell number ( J:99626 )

• approximately 23% of CA1 pyramidal cells remaining at 8.5 months

• CA1 neuron estimates were stabilized after brief (6- to 8-week) doxycycline treatment

behavior/neurological

abnormal spatial learning ( J:99626 )

• he retention of spatial memory examined by the Morris water maze were impaired as the mice aged

• deficit in spatial navigation was also seen in younger mice

• the performance improved when treated with doxycycline at 2.5 month-old or at 5.5 month-old

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
Alzheimer's disease		DOID:10652		J:99626